Cargando…

Patients’ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire

INTRODUCTION: Understanding patients’ preferences for long-acting injectable (LAI) or oral antipsychotics (pills) could help reduce potential barriers to LAI use in schizophrenia. METHODS: Post hoc analyses were conducted from a double-blind, randomized, non-inferiority study (NCT01515423) of 3-mont...

Descripción completa

Detalles Bibliográficos
Autores principales: Blackwood, Clifton, Sanga, Panna, Nuamah, Isaac, Keenan, Alexander, Singh, Arun, Mathews, Maju, Gopal, Srihari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342487/
https://www.ncbi.nlm.nih.gov/pubmed/32753849
http://dx.doi.org/10.2147/PPA.S251812
_version_ 1783555499576262656
author Blackwood, Clifton
Sanga, Panna
Nuamah, Isaac
Keenan, Alexander
Singh, Arun
Mathews, Maju
Gopal, Srihari
author_facet Blackwood, Clifton
Sanga, Panna
Nuamah, Isaac
Keenan, Alexander
Singh, Arun
Mathews, Maju
Gopal, Srihari
author_sort Blackwood, Clifton
collection PubMed
description INTRODUCTION: Understanding patients’ preferences for long-acting injectable (LAI) or oral antipsychotics (pills) could help reduce potential barriers to LAI use in schizophrenia. METHODS: Post hoc analyses were conducted from a double-blind, randomized, non-inferiority study (NCT01515423) of 3-monthly vs 1-monthly paliperidone palmitate in patients with schizophrenia. Data from the Medication Preference Questionnaire, administered on day 1 (baseline; open-label stabilization phase), were analyzed. The questionnaire includes four sets of items: 1) reasons for general treatment preference based on goals/outcomes and preference for LAI vs pills based on 2) personal experience, 3) injection-site (deltoid vs gluteal), 4) dosing frequency (3-monthly vs 1-monthly). A logistic regression analysis was performed to assess the effect of baseline variables on preference (LAIs or pills). RESULTS: Data from 1402 patients were available for analysis. Patients who preferred LAIs recognized these outcomes as important: “I feel more healthy” (57%), “I can get back to my favorite activities” (56%), “I don’t have to think about taking my medicines” (54%). Most common reasons for medication preference (LAI vs pills) were: “LAIs/pills are easier for me” (67% vs 18%), “more in control/don’t have to think about taking medicine” (64% vs 14%), “less pain/sudden symptoms” (38% vs 18%) and “less embarrassed” (0% vs 46%). Majority of patients (59%) preferred deltoid over gluteal injections (reasons: faster administration [63%], easier [51%], less embarrassing [44%]). In total, 50% of patients preferred 3-monthly over 1-monthly (38%) or every day (3%) dosing citing reasons: fewer injections [96%], fewer injections are less painful [84%], and fewer doctor visits [80%]. From logistic regression analysis, 77% of patients preferred LAI over pills; culture and race appeared to play a role in this preference. CONCLUSION: Patients who preferred LAI antipsychotics prioritized self-empowerment and quality-of-life-related goals. When given the option, patients preferred less-frequent, quarterly injections over monthly injections and daily oral medications.
format Online
Article
Text
id pubmed-7342487
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-73424872020-08-03 Patients’ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire Blackwood, Clifton Sanga, Panna Nuamah, Isaac Keenan, Alexander Singh, Arun Mathews, Maju Gopal, Srihari Patient Prefer Adherence Original Research INTRODUCTION: Understanding patients’ preferences for long-acting injectable (LAI) or oral antipsychotics (pills) could help reduce potential barriers to LAI use in schizophrenia. METHODS: Post hoc analyses were conducted from a double-blind, randomized, non-inferiority study (NCT01515423) of 3-monthly vs 1-monthly paliperidone palmitate in patients with schizophrenia. Data from the Medication Preference Questionnaire, administered on day 1 (baseline; open-label stabilization phase), were analyzed. The questionnaire includes four sets of items: 1) reasons for general treatment preference based on goals/outcomes and preference for LAI vs pills based on 2) personal experience, 3) injection-site (deltoid vs gluteal), 4) dosing frequency (3-monthly vs 1-monthly). A logistic regression analysis was performed to assess the effect of baseline variables on preference (LAIs or pills). RESULTS: Data from 1402 patients were available for analysis. Patients who preferred LAIs recognized these outcomes as important: “I feel more healthy” (57%), “I can get back to my favorite activities” (56%), “I don’t have to think about taking my medicines” (54%). Most common reasons for medication preference (LAI vs pills) were: “LAIs/pills are easier for me” (67% vs 18%), “more in control/don’t have to think about taking medicine” (64% vs 14%), “less pain/sudden symptoms” (38% vs 18%) and “less embarrassed” (0% vs 46%). Majority of patients (59%) preferred deltoid over gluteal injections (reasons: faster administration [63%], easier [51%], less embarrassing [44%]). In total, 50% of patients preferred 3-monthly over 1-monthly (38%) or every day (3%) dosing citing reasons: fewer injections [96%], fewer injections are less painful [84%], and fewer doctor visits [80%]. From logistic regression analysis, 77% of patients preferred LAI over pills; culture and race appeared to play a role in this preference. CONCLUSION: Patients who preferred LAI antipsychotics prioritized self-empowerment and quality-of-life-related goals. When given the option, patients preferred less-frequent, quarterly injections over monthly injections and daily oral medications. Dove 2020-07-02 /pmc/articles/PMC7342487/ /pubmed/32753849 http://dx.doi.org/10.2147/PPA.S251812 Text en © 2020 Blackwood et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Blackwood, Clifton
Sanga, Panna
Nuamah, Isaac
Keenan, Alexander
Singh, Arun
Mathews, Maju
Gopal, Srihari
Patients’ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire
title Patients’ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire
title_full Patients’ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire
title_fullStr Patients’ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire
title_full_unstemmed Patients’ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire
title_short Patients’ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire
title_sort patients’ preference for long-acting injectable versus oral antipsychotics in schizophrenia: results from the patient-reported medication preference questionnaire
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342487/
https://www.ncbi.nlm.nih.gov/pubmed/32753849
http://dx.doi.org/10.2147/PPA.S251812
work_keys_str_mv AT blackwoodclifton patientspreferenceforlongactinginjectableversusoralantipsychoticsinschizophreniaresultsfromthepatientreportedmedicationpreferencequestionnaire
AT sangapanna patientspreferenceforlongactinginjectableversusoralantipsychoticsinschizophreniaresultsfromthepatientreportedmedicationpreferencequestionnaire
AT nuamahisaac patientspreferenceforlongactinginjectableversusoralantipsychoticsinschizophreniaresultsfromthepatientreportedmedicationpreferencequestionnaire
AT keenanalexander patientspreferenceforlongactinginjectableversusoralantipsychoticsinschizophreniaresultsfromthepatientreportedmedicationpreferencequestionnaire
AT singharun patientspreferenceforlongactinginjectableversusoralantipsychoticsinschizophreniaresultsfromthepatientreportedmedicationpreferencequestionnaire
AT mathewsmaju patientspreferenceforlongactinginjectableversusoralantipsychoticsinschizophreniaresultsfromthepatientreportedmedicationpreferencequestionnaire
AT gopalsrihari patientspreferenceforlongactinginjectableversusoralantipsychoticsinschizophreniaresultsfromthepatientreportedmedicationpreferencequestionnaire